(S044) Patient-Reported Quality of Life After Stereotactic Body Radiotherapy (SBRT), Intensity-Modulated Radiotherapy (IMRT), and Brachytherapy

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

There were slightly smaller declines in bowel QoL after SBRT and slightly larger declines in urinary QoL after brachytherapy. While QoL after SBRT, IMRT, or brachytherapy is largely similar and supports SBRT as a reasonable radiotherapy option for localized prostate cancer, a randomized comparison is needed for the strongest evidence.

Joseph R. Evans, MD, PhD, Shuang Zhao, MSE, Stephanie Daignault, MS, Martin G. Sanda, MD, Jeff Michalski, MD, Howard M. Sandler, MD, Deborah A. Kuban, MD, Jay Ciezki, MD, Irving D. Kaplan, MD, Anthony L. Zietman, MD, Larry Hembroff, PhD, Felix Y. Feng, MD, Simeng Suy, PhD, Ted A. Skolarus, MD, P. William McLaughlin, MD, John T. Wei, MD, Rodney L. Dunn, MS, Steven E. Finkelstein, MD, Constantine A. Mantz, MD, Sean P. Collins, MD, PhD, Daniel A. Hamstra, MD, PhD; University of Michigan; Emory University; Washington University; Cedars-Sinai Medical Center; UT MD Anderson Cancer Center; Cleveland Clinic; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Michigan State University; Georgetown University; University of Michigan; VA Ann Arbor Healthcare System; 21st Century Oncology

BACKGROUND: Stereotactic body radiotherapy (SBRT) is gaining popularity as a radiotherapy option for localized prostate cancer that is less invasive than brachytherapy and less costly and time-intensive than intensity-modulated radiotherapy (IMRT). However, there are ongoing concerns about excess toxicity after SBRT compared with other radiotherapy options.

METHODS: We conducted a multi-institutional pooled cohort analysis of patient-reported quality of life (QoL) using the Expanded Prostate Cancer Index (EPIC-26) survey collected serially from baseline to 2 years. Men were treated with IMRT, brachytherapy, or SBRT at multiple institutions. Mean EPIC symptom domain scores were evaluated, as was the proportion of patients with a minimal clinically detectable difference (MCD) in each domain. Multivariate analyses were used to determine the independence and association of standard clinical variables and treatment type with domain scores at 2 years. Sensitivity analysis was performed for 12-Item Short Form Health Survey (SF-12) data, as a minor proportion of the SBRT patients were missing SF-12 data, and for year of IMRT treatment, as we suspected that IMRT technique may have evolved over time, which would be expected to decrease toxicity and reduce the impact on QoL.

RESULTS: Data were analyzed from 803 patients at baseline and from 645 patients at 2 years. Mean declines at 2 years across all patients were −1.9, −4.8, −4.9, and −13.3 points for the urinary obstructive, urinary incontinence, bowel, and sexual symptom domains, respectively. Based upon MCD, 29%, 20%, and 28% of all patients had detectable differences in urinary, bowel, and sexual domains, respectively, at 2 years. On multivariate analysis, brachytherapy had worse urinary irritation (−6.8 [−9.9, −3.6] points vs IMRT, P < .0001; −5.8 points [−9, −2.5] vs SBRT, P < .0001), but there were no differences in the bowel (P = .48), urinary incontinence (P = .21), or sexual domains (P = .18). QoL after SBRT was similar to IMRT for the urinary (P = .55, obstruction; P = .74, incontinence) and sexual domains (P = .57) but was associated with better bowel score (+6.7 [3.2, 10] vs IMRT, P < .0002; +5.5 [2.2, 8.8] vs brachytherapy, P = .001). We observed a positive association between SF-12 Mental and Physical component scores and 2-year domain scores for nearly all domains. Sensitivity analyses demonstrated a minimal effect of missing SF-12 data and no changes in 2-year domain scores with year of IMRT treatment.

CONCLUSIONS: There were slightly smaller declines in bowel QoL after SBRT and slightly larger declines in urinary QoL after brachytherapy. While QoL after SBRT, IMRT, or brachytherapy is largely similar and supports SBRT as a reasonable radiotherapy option for localized prostate cancer, a randomized comparison is needed for the strongest evidence.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content